Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Fisher, Julie G., Tait, David, Garrett-Mayer, Elizabeth, Halabi, Susan, Mangat, Pam K., Schink, Julian C., Alvarez, Ricardo H., Veljovich, Dan, Cannon, Timothy L., Crilley, Pamela A., Pollock, Theodore, Calfa, Carmen J., Al Baghdadi, Tareq, Thota, Ramya, Fleming, Nicole, Cotta, Jared A., Rygiel, Andrew L., Warren, Sasha L., Schilsky, Richard L.
Published in Targeted oncology (01.12.2020)
Published in Targeted oncology (01.12.2020)
Get full text
Journal Article
Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reported KRAS, NRAS, BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Fisher, Julie, Garrett-Mayer, Elizabeth, Halabi, Susan, Mangat, Pam K., Alvarez, Ricardo H., Cannon, Timothy L., Crilley, Pamela, Pollock, Theodore, Baghdadi, Tareq Al, Cotta, Jared A., Rygiel, Andrew L., Antonelli, Kaitlyn R., Islam, Samiha, Bruinooge, Suanna S., Schilsky, Richard L.
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article